Navigation Links
Mayo Clinic and ReachMD Launch “Updates from Mayo Clinic” Featuring Expert Interviews and Panel Discussions on Mental Health in Pediatric Primary Care
Date:5/31/2013

Fort Washington, PA (PRWEB) May 31, 2013

ReachMD, an award-winning producer and nationwide distributor of healthcare information and education for medical professionals, announced today its collaboration with Mayo Clinic on a new series titled Updates from Mayo Clinic. Hosted by Dr. Peter S. Jensen, Professor of Psychiatry and Vice Chair for Research at Mayo Clinic in Rochester, Minnesota, the series launches with a focus on recent advances in the management of psychiatric and neurologic disorders in the pediatric population.

Each broadcast segment is 15 minutes and features host Dr. Jensen with renowned guests from academic centers, medical institutions, and societies. The series broadcasts on air on XM Satellite Radio Channel 245, is simulcast online on ReachMD.com, and can be downloaded on demand through the free MedicalRadio™ app available on iTunes.

"We are pleased to launch this Series in collaboration with ReachMD to capture insights from medical experts across the country in the constantly evolving realm of psychiatric and neurologic disorders,” said Dr. Jensen, host of the series.

Dr. Jensen’s interviews span a spectrum of mental health management issues in pediatric primary care, including:

  • Limiting Overprescribing vs Underprescribing of ADHD Medications
  • The Role of Evidence-based Therapies in Treating Childhood Anxiety
  • Addressing Suicidality in Adolescents and Young Adults
  • Controversies in Diagnosis of Pediatric Bipolar Disorder
  • Integrating Mental Health Expertise into Primary Care
  • Substance Use vs Abuse in Teenagers With ADHD

“The Updates from Mayo Clinic series brings enormous value to our listeners, and through expert interviews and panel discussions, we can broaden the understanding of pediatric mental health,” said Dr. Matt Birnholz, Medical Director at ReachMD and resident host of the radio station.

The series is supported through an educational grant from Shire Pharmaceuticals.

About ReachMD
ReachMD is the first and only national radio channel for healthcare professionals that broadcasts information and education 24/7 on XM Satellite Channel 245, streams simulcasts on ReachMD.com, offers on-demand podcasts online and through the ReachMD MedicalRadio app, and communicates weekly with subscribers through e-programming guides. ReachMD leverages its proprietary broadcast technologies to deliver compelling content geared to help time-constrained healthcare professionals stay abreast of research, expert commentary, treatment protocols, conference coverage, and CME requirements.

About Mayo Clinic
Mayo Clinic is a nonprofit worldwide leader in medical care, research and education for people from all walks of life. For more information, visit MayoClinic.com.

Read the full story at http://www.prweb.com/releases/Mayo/ReachMD/prweb10779726.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. FDA Review in Journal for ImmunoTherapy of Cancer Offers New Insights into Cancer Immunotherapy Product Development & Clinical Evaluation
2. Cynvenio Biosystems to Present Clinical Data on Mutational Analysis of LiquidBiopsy® Tumor Samples at the 2013 ASCO Annual Meeting
3. Adhering to Good Clinical Practice, New Webinar Hosted by Xtalks
4. Disruptive Innovation Hits Clinical Trials, Dedicated Event Launches
5. Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
6. ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials
7. MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer
8. Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation.
9. Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS)
10. Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis
11. Computational Analysis in Clinical and Preclinical Decision-Making, new webinar hosted by Xtalks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... Huffman Engineering, ... become a Wonderware Certified System Integrator Partner. Huffman Engineering is the only ... , “The System Integrator Partner certification gives customers confidence that our engineers are ...
(Date:12/7/2016)... /PRNewswire/ - OncoQuest Inc. ("OncoQuest"), a biopharmaceutical company ... products for the treatment of cancer, today announced ... Development Program with Cytovance Biologics ( Oklahoma ... antibody product. Supported by recent positive interim clinical ... ovarian cancer patients, OncoQuest has engaged Cytovance to ...
(Date:12/7/2016)... Ontario , Dec. 7, 2016  Nordion, ... with General Atomics (GA), welcome today,s award by ... Nuclear Security Administration (NNSA) of the Phase II ... project with Nordion and the University of Missouri ... II funding will support the establishment of a ...
(Date:12/7/2016)... , December 8, 2016 The report "Acrylic Processing Aid Market by ... Packaging, Automotive, Consumer Goods) - Global Forecast to 2026", published by MarketsandMarkets, the ... reach USD 1,173.6 Million by 2026, registering an of CAGR of 6.2% between ... ... MarketsandMarkets Logo ...
Breaking Biology Technology:
(Date:12/7/2016)... 2016   Veridium , a leader in ... new CEO James Stickland . Stickland, a ... experience, has served in senior executive roles for ... in expanding a pipeline of venture capital and ... recently served as managing director of U.K.-based fintech ...
(Date:12/6/2016)... 2016 Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring, and the ... five (5) year funding commitment by Securus to ... rehabilitation and reentry support to more inmates and ... 2004, the Prison Entrepreneurship Program (PEP) is an ...
(Date:12/2/2016)... , Dec. 1, 2016   SoftServe , ... BioLock , an electrocardiogram (ECG) biosensor analysis ... a key IoT asset. The smart system ensures ... vehicle,s steering wheel and mobile devices to easily ... As vehicle technology advances, so too ...
Breaking Biology News(10 mins):